{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sweat&page=3",
    "query": {
      "condition": "Sweat",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 290,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sweat&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Sweat&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T14:18:27.028Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07414810",
      "title": "Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "micro Sweat Test Patch (mSTP)",
          "type": "DEVICE"
        },
        {
          "name": "Sweat Testing using SOC",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Weeks",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "2 Weeks to 90 Years"
      },
      "enrollment_count": 300,
      "start_date": "2026-11",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-27",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07414810"
    },
    {
      "nct_id": "NCT01671800",
      "title": "Study to Assess the Efficacy of Botulinum Toxin B (Myobloc) for the Treatment of Prosthesis-associated Sweating",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperhidrosis"
      ],
      "interventions": [
        {
          "name": "Botulinum Type B",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Henry M. Jackson Foundation for the Advancement of Military Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 20,
      "start_date": "2008-09",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2013-01-10",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01671800"
    },
    {
      "nct_id": "NCT03569371",
      "title": "A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "INCB054707",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Incyte Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 10,
      "start_date": "2018-07-17",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Tampa, Florida • New York, New York + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03569371"
    },
    {
      "nct_id": "NCT04246372",
      "title": "Tofacitinib for Immune Skin Conditions in Down Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Down Syndrome",
        "Alopecia Areata",
        "Atopic Dermatitis / Eczema",
        "Hidradenitis Suppurativa",
        "Vitiligo",
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "12 Years to 50 Years"
      },
      "enrollment_count": 47,
      "start_date": "2020-10-21",
      "completion_date": "2024-10-30",
      "has_results": true,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04246372"
    },
    {
      "nct_id": "NCT02193139",
      "title": "Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperhidrosis"
      ],
      "interventions": [
        {
          "name": "WL8713, 6 mg",
          "type": "DRUG"
        },
        {
          "name": "WL8713, 12 mg",
          "type": "DRUG"
        },
        {
          "name": "WL8713, 18 mg",
          "type": "DRUG"
        },
        {
          "name": "WL8713, 24 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Watson Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 195,
      "start_date": "2013-12",
      "completion_date": "2014-06",
      "has_results": false,
      "last_update_posted_date": "2015-08-06",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02193139"
    },
    {
      "nct_id": "NCT04901195",
      "title": "A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 658,
      "start_date": "2021-05-27",
      "completion_date": "2026-07-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 43,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04901195"
    },
    {
      "nct_id": "NCT00071877",
      "title": "An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Replagal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 25,
      "start_date": "2003-10",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00071877"
    },
    {
      "nct_id": "NCT07263230",
      "title": "The Safety and Efficacy of Roflumilast Foam in HS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa (HS)"
      ],
      "interventions": [
        {
          "name": "Roflumilast 0.3% topical foam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-09-01",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-09",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07263230"
    },
    {
      "nct_id": "NCT02695212",
      "title": "Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa"
      ],
      "interventions": [
        {
          "name": "Apremilast",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Florida Academic Dermatology Centers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2016-07",
      "completion_date": "2017-08",
      "has_results": false,
      "last_update_posted_date": "2019-04-02",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 1,
      "location_summary": "Coral Gables, Florida",
      "locations": [
        {
          "city": "Coral Gables",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02695212"
    },
    {
      "nct_id": "NCT07783542",
      "title": "ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hidradenitis Suppurativa (HS)"
      ],
      "interventions": [
        {
          "name": "ORKA-002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Oruka Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "79 Years",
        "sex": "ALL",
        "summary": "18 Years to 79 Years"
      },
      "enrollment_count": 200,
      "start_date": "2026-08-21",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-29",
      "last_synced_at": "2026-10-29T14:18:27.028Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Cromwell",
          "state": "Connecticut"
        },
        {
          "city": "Sandy Springs",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07783542"
    }
  ]
}